Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study

 This is probably not going to help hemorrhage risk post tPA treatment since they refer to longer duration use. 

Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study

Nils Jensen Boe, View ORCID ProfileStine Munk Hald, View ORCID ProfileMie Micheelsen Jensen, View ORCID ProfileJonas Asgaard Bojsen, View ORCID ProfileMohammad Talal Elhakim, Sandra Florisson, Alisa Saleh, Anne Clausen, Sören Möller, View ORCID ProfileFrederik Severin Gråe Harbo, Ole Graumann, Jesper Hallas, View ORCID ProfileLuis Alberto García Rodríguez, View ORCID ProfileRustam Al-Shahi Salman, View ORCID ProfileLarry B. Goldstein, View ORCID ProfileDavid Gaist

First published December 7, 2022, DOI: https://doi.org/10.1212/WNL.0000000000201664

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

0

Add to Cart ($39)

• Article
• Info & Disclosures

Abstract

Background: A causal relationship between statin use and intracerebral hemorrhage (ICH) is uncertain. We hypothesized that an association between long-term statin exposure and ICH risk might vary for different ICH locations.

Methods: We conducted this analysis using linked Danish nationwide registries. Within the Southern Denmark Region (population 1.2 million), we identified all first-ever cases of ICH between 2009-2018 in persons ages >55 years. Patients with medical record verified diagnoses were classified as having a lobar or non-lobar ICH and matched for age, sex, and calendar year to general population controls. We used a nationwide prescription registry to ascertain prior statin and other medication use that we classified for recency, duration, and intensity. Using conditional logistic regression adjusted for potential confounders, we calculated adjusted odds ratios (aORs) and corresponding 95% Confidence Intervals (CIs) for the risk of lobar and non-lobar ICH.

Results: We identified 989 patients with lobar ICH (52.2% women, mean age 76.3-years) who we matched to 39,500 controls, and 1,175 patients with non-lobar ICH (46.5% women, mean age 75.1-years) who we matched to 46,755 controls. Current statin use was associated with a lower risk of lobar (aOR 0.83; 95%CI, 0.70-0.98) and non-lobar ICH (aOR 0.84; 95%CI, 0.72-0.98). Longer duration of statin use was also associated with lower risk of lobar (<1 year: aOR 0.89; 95%CI, 0.69-1.14; ≥1 year to <5years aOR 0.89; 95%CI 0.73-1.09; ≥5 years aOR 0.67; 95%CI, 0.51-0.87; p for trend 0.040) and non-lobar ICH (<1 year: aOR1.00; 95%CI, 0.80-1.25; ≥1 year to <5years aOR 0.88; 95%CI 0.73-1.06; ≥5 years aOR 0.62; 95%CI, 0.48-0.80; p for trend <0.001). Estimates stratified by statin intensity were similar to the main estimates for low-medium intensity therapy (lobar aOR 0.82; non-lobar aOR 0.84); the association with high intensity therapy was neutral.

Discussion: We found that statin use was associated with a lower risk of ICH, particularly with longer treatment duration. This association did not vary by hematoma location.

• Received August 29, 2022.
• Accepted in final form October 24, 2022.

• © 2022 American Academy of Neurology